Strategy to detect pre-existing immunity to AAV gene therapy-Reference-Cited by-同舟云学术

Strategy to detect pre-existing immunity to AAV gene therapy

Published:2017-11-06 Issue:12 Volume:24 Page:768-778
ISSN:0969-7128
Container-title:Gene Therapy
language:en
Short-container-title:Gene Ther

Author:

Falese L^ORCID,Sandza K^ORCID,Yates B,Triffault S,Gangar S,Long B,Tsuruda L,Carter B,Vettermann C,Zoog S J,Fong S

Publisher

Springer Science and Business Media LLC

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/gt201795.pdf

Reference41 articles.

1. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371: 1994–2004.

2. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357–2365.

3. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257–261.

4. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342–347.

5. Genetic Modification Clinical Research System. Version 6.2. Available at: https://www.gemcris.od.nih.gov/Contents/GC_HOME.asp . Accessed 7 October 2016.

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies;Molecular Therapy - Methods & Clinical Development;2024-09

2. Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A;Molecular Therapy;2024-07

3. Hybrid modeling of an ultracentrifugation process for separation of full and empty adeno-associated virus particles;Bioprocess and Biosystems Engineering;2024-05-04

4. Adeno-associated virus as a delivery vector for gene therapy of human diseases;Signal Transduction and Targeted Therapy;2024-04-03

5. Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirements;Molecular Therapy - Methods & Clinical Development;2024-03